Verenium — Investor Day (October 2012)
91 slides from Verenium's investor day presentation, Oct 9, 2012
Slide 1: Verenium's 2012 Capital Markets Day
Verenium’s 2012 Capital Markets Day Introduction to Verenium’s Strategy James Levine President & CEO October 9, 2012
Slide 2: Forward Looking Statements
2 Forward Looking Statements Verenium, the Verenium logo, Industry, Evolved., Fuelzyme ® alpha-amylase, Pyrolase ® cellulase, Pyrolase ® HT, Vereflow TM alpha- amylase and Xylathin ® xylanase are trademarks of Verenium. All other company names, product names or logos in this presentation are used fo
Slide 3: June 2011 Capital Markets Day: Expected Milestones Through 2013
Current Product Growth Product Diversification Manufacturing New Products Product Pipeline New Market(s) Technology Financial 3 June 2011 Capital Markets Day: Expected Milestones Through 2013 Accelerate growth in current 9 commercial products Achieve 50% of 2011 revenue from products / partnerships
Slide 4: Defining Verenium: Are We a Clean Tech Company?
4 Defining Verenium: Are We a “Clean Tech” Company? Harness renewable materials and energy sources Dramatically reduce the use of natural resources Cut or eliminate emissions and wastes Are competitive with, if not superior to, their conventional counterparts Offer significant additional benefits Wi
Slide 5: Defining Verenium: We Don't Face Clean Tech's Risks
5 Verenium’s Lower Risk Profile Proven technology platform with 10 products commercially launched Manufacture products at full commercial scale Largest product – Phyzyme® phytase – captured a market leading share in a major enzymes market Ability to scale manufacturing with current fermentation asse
Slide 6: Industrial Enzymes Have Broad Applicability in Our Everyday Lives
6 Defining Our Industry: Industrial Enzymes Have Broad Applicability in Our Everyday Lives
Slide 7: Verenium's Target Markets for Industrial Enzymes
7 We Target Profitable and Growing Markets that Exist Today Defining Our Industry: Verenium’s Target Markets for Industrial Enzymes Addressed by Verenium’s Current 8 Products Source: Market size estimates based on Verenium internal estimates and L. Hepner & Associates Industrial Enzymes Report publi
Slide 8: Major Players in the Industrial Enzymes Market
Verenium has a Track Record of Competing on Product Performance 8 Increasing Cost Competitiveness Novozymes DuPont (Genencor) DSM BASF Defining Our Industry: Major Players in the Industrial Enzymes Market AB Enzymes Verenium
Slide 9: Verenium has Demonstrated the Full Suite of Core Capabilities
CONCEPTUALIZE Products CREATE Products MANUFACTURE Products MARKET Products 9 Industrial Enzymes Core Capabilities: Verenium has Demonstrated the Full Suite Define Unmet Needs: addressable with enzymes Determine Value Proposition: for partners and customers Verenium’s Position: Solid track record of
Slide 10: Our Business Model and Value Proposition
Product Pipeline Expansion Pipeline Demonstrates Commercial Success Path to $100M+ Revenue Path to $200M+ Revenue CREATE Products 10 Commercial Products Defining Our Business Model and Value Proposition Capabilities: Discovery, evolution, expression and approval of optimized enzyme Verenium’s Positi
Slide 11: Past & Present Partners Validate Our Products and Technology
11 TECHNOLOGY SUITE ANIMAL HEALTH GRAIN PROCESSING OILFIELD SERVICES Past & Present Partners Validate the Strength and Uniqueness of Our Products and Technology We developed enzymes and discovery and evolution technologies used in BP’s cellulosic enzyme program We created a unique Phospholipase C pr
Slide 12: The Management Team that Will Execute
12 • Joined Verenium in 1997 as a Senior Scientist and has held a variety of R&D positions with the Company • Previously pursued research fellowships at Scripps Research Institute in La Jolla, CA and Amherst College David Weiner, VP of R&D Strategy, Innovation & Partnerships The Management Team that
Slide 13: Commercial Products, Pipeline Products, Manufacturing
Commercial Products Pipeline Products Manufacturing Janet Roemer Chief Operating Officer October 9, 2012
Slide 14: Industrial Enzymes: Profitable, Growing Markets Today, New Markets Emerging
14 Margins of market leader Gross Margins>55% EBIT Margins >20% Industrial Enzymes: Profitable, Growing Markets Today, New Markets Emerging Source: Verenium/L.Hepner & Associates. $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 2012 2014 2016 Oilfield Services Sweetener Enzymes Technical Enzymes Nutrit
Slide 15: Verenium's Unique Lead Commercial Products
15 ANIMAL HEALTH AND NUTRITION Lead Product, $350M+ Market Verenium’s Unique Lead Commercial Products Market-Validated with $55M in LTM Revenue Addressing $1B Opportunity GRAIN PROCESSING $400M+ Market OILFIELD SERVICES Up to $270M* Combined Market In Hydraulic Fracturing & Filter Cake Removal Sourc
Slide 16: Verenium's Product Pipeline
16 Product Candidate Potential Market Size (2016)* Estimated Launch Target Market Position Animal Health & Nutrition Enzymes Grain Processing Enzymes Oilfield Services Enzymes Verenium’s Product Pipeline Path to Revenue Growth and Operating Profitability Next-Gen Phytase $400 - 450M 2013 - 2015 Majo
Slide 17: Animal Health and Nutrition
17 ANIMAL HEALTH AND NUTRITION Lead Product, $350M+ Market Verenium’s Unique Lead Commercial Products
Slide 18: Animal Health and Nutrition Enzymes: Large and Growing Market
• Nearly $600m growing to > $700M by 2016 • Growing in all regions • Enzymes proven to increase options for feed formulation • Improve efficiency – feed conversion • Faster animal growth, better health, more uniform production • Potential for additional enzymes, new target species 18 1000 2011 2016
Slide 19: Phytase Enzymes Growth is Due to Numerous Advantages
Enzymes release phosphorus naturally occurring in grains but bound up in phytate Provide additional value by releasing other essential nutrients complexed by phytate Sustainable alternative to a mined product Safeguards the environment – reduced phosphorus in animal waste Biodegradable 19 Phytase En
Slide 20: Phytase Enzymes Growth is Due to Numerous Advantages over Inorganic Phosphorus
20 Phytase Enzymes Growth is Due to Numerous Advantages over Inorganic Phosphorus Sustainable alternative to a mined product Safeguards the environment – reduced Phosphorus in waste Biodegradable Minute quantities relative to inorganic phosphate Provide additional nutritional value by releasing mine
Slide 21: Phyzyme Phytase – Differentiated, Category-Leading Product
21 BACTERIAL PHYTASE - DIFFERENTIATED FROM FUNGAL PHYTASES MULTIPLE MANUFACTURING SITES DUPONT MARKETING • More active in the digestive tract • Active longer • Lower dose, higher feed conversion ratio • Global manufacturing • Efficient supply chain • Broad product portfolio • Expertise in animal nut
Slide 22: Verenium's Partnership with Novus International
• Next Generation Phytase • Non Starch Polysaccharide (NSP) cocktail of 3 enzymes 22 More than 800 employee serving more than 2500 customers in over 100 countries. Animal Nutrition focus complements Verenium’s 15 years experience in feed enzymes Verenium’s Partnership with Novus International To Acc
Slide 23: To Address a Broader Market Opportunity
23 To Address a Broader Market Opportunity Verenium’s Products Today Market Opportunity 2012 Pipeline Products Launch Targets 2013-2015 Market Opportunity 2016 Pipeline Products For Animal Health and Nutrition – Verenium/Novus Partnership Upside potential in subcategories beyond poultry and pigs, e.
Slide 24: Long-Term Trends Favor Phytase Growth
LONG -TERM TRENDS FAVOR ENZYME GROWTH 24 SHORT- TERM DYNAMICS OF HIGH FEED COST Protein consumption grows with GDP Poultry favored source of protein Continued geographic market penetration Substitute for non-sustainable inorganic phosphorus Benefits from increasing dosage Long-Term Trends Favor Phyt
Slide 25: Verenium's Strategy to Accelerate Growth
25 VERENIUM STRATEGY IN ANIMAL HEALTH & NUTRITION Verenium’s Strategy to Accelerate Growth Maximize Phyzyme gross margin through COGS reduction and global optimization of manufacturing Launch next generation Phytase and NSP enzymes - Novus partnership Pursue additional feed enzyme opportunities Supp
Slide 26: Grain Processing
26 Verenium’s Unique Lead Commercial Products GRAIN PROCESSING $400M+ Market
Slide 27: Grain Processing Enzymes: Moderate Growth, Large Market
$M Addressable Market $M Growth by Region Grain Processing Enzymes Moderate Growth, Large Market Source: Verenium estimates, excludes estimates of cellulosic enzymes, includes estimates of market for new enzymes for process enhancement Source: BCC Research 2012, includes estimates for cellulosic enz
Slide 28: Three High Performance Commercial Products for Grain Processing
28 SLURRY PREPARATION LIQUEFACTION SACCHARIFICATION & FERMENTATION Three High Performance Commercial Products for Grain Processing Increases throughput in cereal-based ethanol plants (wheat, barley, rye – northern climates) $10M market Unique enzyme with multidimensional value proposition $200M mark
Slide 29: Fuelzyme Alpha-Amylase is Differentiated from the Competition by Nature Itself
Superior thermostability, broader pH range & more specific mode of action 29 From a Different Branch on the Phylogenetic Tree of Life Different Mode of Action Produces More Uniform Substrate Most a-amylases Thermococcus Fuelzyme R Fuelzyme Alpha-Amylase is Differentiated from the Competition by Natu
Slide 30: Field Data Demonstrates Value Delivered by Fuelzyme
30 LIQUEFACTION SACCHARIFICATION & FERMENTATION CHEMICAL USAGE Data from 5 trials of Fuelzyme ® Alpha-Amylase at U.S. ethanol plants in 2012 Field Data Demonstrates Value Delivered by Fuelzyme ® Alpha-Amylase Enzyme Dose reduction – Alpha-Amylase Average Savings $148k High Savings $259k Enzyme Dose
Slide 31: Customer Testimonials Highlight Fuelzyme's Plant-Specific Advantages
31 OPERATING FLEXIBILITY CHEMICAL SAVINGS SAFETY AND ENVIRONMENT “Having a broad pH alpha is really nice…to have control about what you want to do is great…Fuelzyme saved the day at this plant.” — Plant Manager Customer Testimonials Highlight Fuelzyme’s Plant-Specific Advantages “Fuelzyme works well
Slide 32: Verenium's Pipeline Products for Grain Processing
NEXT GEN GLUCO AMYLASE PROCESS ENHANCING ENZYMES STARCH MODIFIER 32 • Improved enzyme targeted at a large ($200M+) segment • Unique mode of action enables our partner to create a new product Verenium’s Pipeline Products for Grain Processing Well Positioned to Industry Trends • Two high value “access
Slide 33: Grain Processing: Long-Term Trends and Short-Term Dynamics
LONG-TERM TRENDS SHORT-TERM DYNAMICS OF HIGH OIL & CORN COST 33 Grain Processing Long-Term Trend Toward Biorefinery Model Short-Term Impact of Commodity Pricing Leaders are innovating, adopting new process technologies Biorefinery – multiple feed stocks, multiple products Upside from potential move
Slide 34: Verenium's Grain Processing Strategy
34 VERENIUM GRAIN PROCESSING STRATEGY KEY TACTICS Verenium’s Grain Processing Strategy Grow through Share Gain and New Products • Variety of offers to encourage field trials • Document sources of value creation and price to share value • Technical reviews to add value to relationships • Continual im
Slide 35: Oilfield Services
35 Verenium’s Unique Lead Commercial Products OILFIELD SERVICES Up to $270M* Combined Market In Hydraulic Fracturing & Filter Cake Removal
Slide 36: Unconventional Drilling and Stimulation Techniques
Horizontal drilling technology Generally deeper than conventional wells Impermeable, hard rock – impedes flow Wide range of pH and temperature conditions Water, chemical usage, and especially “fracking” techniques subject of public concern and debate 36 “All of the Above” Energy Strategy Requires Un
Slide 37: Cellulase Enzyme for Hydraulic Fracturing
37 Providing Favorable Performance and Environmental Benefits PERFORMANCE ECONOMICS ENVIRONMENTAL Before enzyme is inactive guar is viscous After enzyme is active guar is “broken” Oilfield Services Cellulase Enzyme for Hydraulic Fracturing Superior economics relative to chemicals used in the process
Slide 38: Pipeline Product for Oilfield Services: Pyrolase HT
38 Performance data included in the SPE paper. Due to its specificity, “Mannanase” (Pyrolase ® HT) leaves far less residue than the leading chemical breaker (APS – Ammonium persulfate), predicting higher conductivity (flow) of oil and gas. ©2012 SPE. Reproduced with permission of the copyright owner
Slide 39: Verenium Oilfield Services Strategy
39 VERENIUM OILFIELD SERVICES STRATEGY Verenium’s Strategy Drive Major US Service Company Adoption Dedicated sales manager to achieve lab approvals, field trials and conversion to sales Presenting paper at SPE, co-authored with a leading oilfield services company Advertising in trade press to raise
Slide 40: Manufacturing
Manufacturing
Slide 41: Low Cost, Well Established Industrial Scale Process
41 FERMENTATION RECOVERY FORMULATION AND PACKAGING High Value, Novel Enzymes; Low Cost, Well Established Industrial Scale Process Industrial scale modern process based on ancient technology More product specific, advanced equipment and materials Enabling shelf life and usability
Slide 42: Verenium's Manufacturing Strategy
42 Capital-Light with Attractive Margins INVESTMENT PROGRAM TO INCREASE THROUGHPUT AND REDUCE UNIT COST • Improve yields • Upgrade equipment • Faster turnaround time • Improve recovery capability PARTNERSHIP WITH FERMIC IN MEXICO CITY • Partnership reduces our risk • Low capital requirements • Econo
Slide 43: Fuelzyme Manufacturing Performance Improvement
43 Fuelzyme manufacturing performance has been improving in terms of batch yields, consistency and COGS Improvement Example – Fuelzyme Alpha-Amylase Better Yields, and Consistency, COGS • Upgrades to fermentation and recovery to improve yields of Verenium products • Process improvements • Fermic upg
Slide 44: Manufacturing Pilot Plant in San Diego
44 Manufacturing Pilot Plant in San Diego New Capability for Continuous Improvement • • Existing Products: • Pipeline Products: – 40L and 500L fermenters with recovery, product storage – Controls integrated with data historian – Process improvement studies to drive down COGS – Expedites troubleshoot
Slide 45: Verenium
CB VERENIUM
Slide 46: R&D Overview and Outlook
R&D Overview and Outlook David Weiner, Ph.D. Vice President, R&D Strategy & Partnerships October 9, 2012
Slide 47: Proven, Cutting-Edge Technologies = Differentiated Products
47 Proven, Cutting-Edge Technologies = Differentiated Products
Slide 48: Verenium's Unique Suite of Technologies
48 Provides Powerful Competitive Advantage Enzyme Discovery Ultra-high Throughput Screening DirectEvolution® Technologies Applications Expression & Scale-up Verenium’s Unique Suite of Technologies
Slide 49: Enzyme Discovery
TRADITIONAL APPROACH VERENIUM APPROACH FASTER, COMPREHENSIVE, CAPTURES NATURE’S DIVERSITY Typical culturing methods access <0.1% of biodiversity 49 Enzyme Discovery CULTURE MICROBES EXTRACT MICROBIAL DNA Clone Environmental DNA library High throughput enzyme screens Verenium approach is direct, bypa
Slide 50: Unparalleled Global Biodiversity Access
50 Unparalleled Global Biodiversity Access All agreements conform to the Convention on Biological Diversity
Slide 51: Unprecedented Biodiversity
51 Unprecedented Biodiversity • Over 2000 eDNA libraries • Encompass the genomes from over 1 million organisms • Billions of genes, billions of potential new enzymes
Slide 52: Ultra-High Throughput Screening
Versatile Robotic Systems 52 Ultra-high Throughput Screening Ultra-High Throughput Screening
Slide 53: Advanced Automation Technologies
53 ROBOTIC SCREENING SYSTEMS GIGAMATRIX ® PLATFORM Advanced Automation Technologies • Cutting edge, proprietary • Flexible platform • Increased efficiencies, greater reproducibility • Customized 400,000-well microtiter plates • Throughput up to one billion/day • Unprecedented screening of molecular
Slide 54: Development of Pyrolase Cellulase
Verenium Proprietary & Confidential 54 Capturing The Best From Nature • Screened Verenium’s extensive environmental DNA libraries • Discovered multiple candidates • Applications work identified ideal enzyme for fracturing • Scaled-up & commercialized as Pyrolase ® cellulase Development of Pyrolase ®
Slide 55: Development of Pyrolase HT
Improving The Best From Nature 55 Increased temperature range and pH while maintaining unique performance properties of parent enzyme Development of Pyrolase ® HT (~185 o F) (~225 o F)
Slide 56: DirectEvolution Technologies
Evolving The Best From Nature DirectEvolution® Technologies 56 DirectEvolution ® Technologies
Slide 57: Powerful Suite of DirectEvolution Technologies
57 Best variant Starting Enzyme Enzyme variant library Improved variants Powerful Suite of DirectEvolution ® Technologies Diversify Screen Combine variants Repeat if needed
Slide 58: Powerful Suite of DirectEvolution Technologies
Verenium’s Competitive Advantage 58 Better starting points from Nature Proprietary combinatorial assembly methods Proprietary mutagenesis methods & in silico design Advanced automated screening Powerful Suite of DirectEvolution ® Technologies Starting Enzyme Enzyme variant library Improved variants
Slide 59: Proven Capabilities For Targeted Industrial Applications
59 MANUFACTURING ROBUSTNESS PROCESS PERFORMANCE Proven Capabilities For Targeted Industrial Applications DirectEvolution ® Technologies Temperature pH performance Solvent tolerance Substrate specificity Binding affinity (Km) Enzyme turnover (kcat) Relief of inhibition Expression levels Improved reco
Slide 60: Developing Solutions To Real World Problems
Developing Solutions To Real World Problems Applications 60 Applications Science
Slide 61: Focusing on Solutions to Real World Problems
Better Enzymes For Better Processes ANIMAL HEALTH OILFIELD SERVICES 61 GRAIN PROCESSING Focusing on Solutions to Real World Problems Several major oilfield service companies TM SPECIFICATION OF IDEAL ENZYME IDENTIFY MARKET NEED ENZYME DISCOVERY HIGH THROUGHPUT SCREENING ENZYME EVOLUTION
Slide 62: Applications Development
62 Applications Development The value of an idea lies in the using of it -- Thomas Alva Edison (1879) Rapid identification and validation of new product concepts Support for industrial trials & driving product implementations Testing of product candidates in real world applications
Slide 63: Driving Down The Cost Of Goods
Driving Down The Cost Of Goods Expression & Scale-up 63 Expression & Scale-up
Slide 64: System Selection
64 System Selection Heterologous Expression Commercial systems Optimization • Gene optimization • Host engineering • High-throughput screening • Bacteria • Fungi Iterative Fermentation Improvements
Slide 65: Gene Expression & Scale-Up
Pilot Plant R&D Expression Commercial Scale 65 Gene Expression & Scale-Up • Spans L to 10L scale • Develop & optimize expression systems • Scope fermentation conditions • 40L to 500L scale • Develop & optimize commercial processes • Produce material for regulatory & accelerate product launches • Wor
Slide 66: Bridging Innovation to Profits
Commercial Scale R&D Expression Bridging Innovation to Profits 66 Pilot Plant Gene Expression & Scale-Up Scale-up / Scale-down Iterative loops drive continuous process improvements
Slide 67: Unique Discovery and Development Process
Flexible Discovery Process For Finding High-Performance Enzymes VERENIUM ENZYME COLLECTION NEW DISCOVERY & EVOLUTION CURRENT PRODUCT ADJACENCY TIME TO COMMERCIALIZATION More time Less time 67 Unique Discovery and Development Process Development Options • Leverages existing products to new applicatio
Slide 68: Flexible Discovery Process For Finding High-Performance Enzymes
VERENIUM ENZYME COLLECTION NEW DISCOVERY & EVOLUTION CURRENT PRODUCT ADJACENCY TIME TO COMMERCIALIZATION More time Less time Flexible Discovery Process For Finding High-Performance Enzymes 68 Unique Discovery and Development Process Development Options Leverages previous discovery & evolution progra
Slide 69: Verenium's Enzyme Collection
$4 Billion Enzyme Market Opportunity 4,000+ Unique Proprietary Enzymes For Future Products Bioethanol & Sweeteners Animal Health & Nutrition Nutrition Other Detergents Dairy 69 Verenium’s Enzyme Collection Betamannosidases Cellobiohydrolases Cellulases Fucosidases Galactanases Glucanases Mannanases
Slide 70: Verenium's Enzyme Collection
$4 Billion Enzyme Market Opportunity 4,000+ Unique Proprietary Enzymes For Future Products Bioethanol & Sweeteners Animal Health & Nutrition Nutrition Other Detergents Dairy 70 Verenium’s Enzyme Collection Betamannosidases Cellobiohydrolases Cellulases Fucosidases Galactanases Glucanases Mannanases
Slide 71: Starch-based Products in Our Daily Lives
71 Starch-based Products in Our Daily Lives Syrups & Sweeteners Texturizers & thickeners Personal care Pharmaceutical Animal health & nutrition Ethanol Industrial
Slide 72: Diversity of Verenium Starch-Active Enzymes
72 Archaeal -amylase Bacterial -amylase G4-amylase Bacterial -amylase Maltosyltransferase Bacterial -amylase Maltogenic amylase Isoamylase Diversity of Verenium Starch-Active Enzymes Verenium’s proprietary enzymes Verenium’s proprietary enzymes Other (commercial and public domain)
Slide 73: Verenium Amylases
73 Verenium Amylases Unique enzymes, functionalities Operate over wide range of conditions New toolbox to create new products G2 amylase G4 amylase Isoamylase (debranching)
Slide 74: Verenium's Expansion Pipeline: Targeted Markets
ANIMAL HEALTH OILFIELD SERVICES GRAIN PROCESSING BAKING PERSONAL CARE SWEETENERS DETERGENTS /CLEANERS 74 Verenium’s Expansion Pipeline: Targeted Markets New Products for Current Markets New Products for New Markets
Slide 75: Intellectual Property Portfolio
Substantial Protection For Our Technology And Our Products 75 Intellectual Property Portfolio *Includes owned and in-licensed patents 369 granted, 353 pending (722 total)* Discovery Evolution Other Product Pipeline & Expansion Pipeline Since July 2011: 13 US patents issued 20 new patent filings & ID
Slide 76: High Performance Enzymes For A Sustainable Economy
Proven, best-in-class discovery & evolution technologies Extensive applications & product development expertise Track record of successful product commercialization & partnerships 76 High Performance Enzymes For A Sustainable Economy RAPID ACCESS TO UNIQUE ENZYMES SUPERIOR PRODUCTS PATH TO PROFITS
Slide 77: Achieving Our Financial Goals
Achieving Our Financial Goals Jeffrey Black Chief Financial Officer October 9, 2012
Slide 78: Financial Overview
78 Financial Overview Historical Financial Performance Medium Term Financial Profile Priority Financial Themes Cost control / path to profitability Near-term capital requirements
Slide 79: Improved Overall Financial Profile
79 Improved Overall Financial Profile Financial Overview Major Accomplishments What have we accomplished over last 12 months? Maintained operating expense run rate while increasing level of investment in new product development and commercialization efforts Two quarters of operating income Eliminate
Slide 80: Strong Historical Revenue and Margin Performance
Strong Historical Revenue and Margin Performance 80 Historical Revenue ($M)
Slide 81: Diversifying the Revenue Base
Diversifying the Revenue Base Today Product Revenue = $50M+ Medium-Term Product Revenue = $100M+ 81 15% 22% 63% 10% 20% 40% 30% Medium-Term Product Revenue Profile Animal Health & Nutrition Grain Processing Oilfield Services Other
Slide 82: Targeted Investments in R&D and Sales & Marketing
Targeted Investments in R&D and Sales & Marketing; Holding the Line on G&A 82 Historical Operating Expenses ($M) * Excludes transaction-related gains and / or fees.
Slide 83: Priority Financial Themes
83 Priority Financial Themes Cost Management / Path to Profitability Achieve appropriate levels of R&D and SG&A spend as we continue to align the core business to pure-play enzymes and position ourselves for future growth • R&D growth will come primarily from investment in pipeline • SG&A growth wil
Slide 84: Funding Our Operations to Positive Cash-Flow
84 Phase I (up to $10M now) Phase II (Next 12 months) Funding Our Operations to Positive Cash-Flow Prior Financial Themes Verenium Capital Requirements Source of Funds Timing Purpose • Working capital line • Partnership funding • Debt or equity raise • Cash to execute on business milestones • Fund o
Slide 85: Conclusion
Conclusion James Levine President & CEO October 9, 2012
Slide 86: Verenium's Green Business Model
86 Green 2 Green 1 Green 3 Verenium’s Green Business Model ENVIRONMENTAL Our products are good for the environment CUSTOMER COST SAVINGS Our products save customers money VERENIUM PROFITABILITY Our products generate attractive gross margins
Slide 87: Replacing Expensive Chemistry with Efficient Biology
87 ANIMAL HEALTH OILFIELD SERVICES GRAIN PROCESSING Replacing Expensive Chemistry with Efficient Biology The Basis for Verenium’s Success: We Are Driving Improvements – Today! Ammonium Persulfate used as guar breaker pH adjusted with Ammonia & Sulfuric Acid Mined Dicalcium Phosphate added to diet Ex
Slide 88: Verenium's Expansion Pipeline: Applying Our Technology More Broadly
88 OILFIELD SERVICES GRAIN PROCESSING OILFIELD SERVICES GRAIN PROCESSING BAKING PERSONAL CARE SWEETENERS DETERGENTS/CLEANERS ANIMAL HEALTH Verenium’s Expansion Pipeline: Applying Our Technology More Broadly New Products for Current Markets New Products for New Markets
Slide 89: The Diversified Company We Are Building
89 The Diversified Company We Are Building Product Pipeline and Current Commercial Products $2.5B+ market opportunity from new potential products for: • Animal Health & Nutrition • Oilfield Services • Grain Processing • Detergents & Cleaners • Syrups & Sweeteners • Personal Care • Baking Expansion P
Slide 90: 2012/2013 Milestones To Drive Profitability
Current Product Growth Expansion Pipeline Product Pipeline Product Diversification Financial Manufacturing 90 2012 / 2013 Milestones To Drive Profitability Combined product revenue growth from Grain Processing and Oilfield Services of 25% Complete at least 3 new product development/distribution part
Slide 91: Verenium is "Industry, Evolved."
91 Through our unique access to nature ’ s ever - evolving biodiversity, we create eco-friendly enzyme products that improve performance and lower costs for today’s global industries Verenium is “Industry, Evolved. ”